2019 MRD Conference
I was honored to participate in the 2019 MRD Meeting in NYC hosted by the the MMRF and Memorial Sloan Kettering Cancer Center.
2019 MRD Meeting in NYC
Patient Panel
2019 MRD Meeting in NYC
Patient Panel
October 2 marked the 6th consecutive year of the Advances in
Minimal Residual Disease Testing (MRD) in Myeloma roundtable meeting, a
collaborative effort between Memorial Sloan Kettering Cancer Center and the
MMRF. This meeting is a yearly opportunity for the myeloma community to come
together to discuss the use of MRD testing in clinical practice and the
progress toward its acceptance (by FDA) as a surrogate clinical endpoint for
myeloma clinical trials.
Attendees are a cross-section of the myeloma community,
including leading myeloma physicians, pharmaceutical company representatives,
scientists, and this year, for the first time, patient representatives. All of them came prepared to debate a number
of topics related to MRD measurement in myeloma. In each session, audience
opinions were assessed before and after the presentations to determine if the
arguments succeeded in changing these opinions.
Comments
Post a Comment